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Since 1999, oxidative damage to RNA molecules has been described in several neurological diseases including Alzheimer’s disease,
Parkinson’s disease, Down syndrome, dementia with Lewy bodies, prion disease, subacute sclerosing panencephalitis, and xero-
dermapigmentosum.AnearlyinvolvementofRNAoxidationofvulnerableneuronalpopulationintheneurodegenerativediseases
has been demonstrated, which is strongly supported by a recent observation of increased RNA oxidation in brains of subjects with
mild cognitive impairment. Until recently, little is known about consequences and cellular handling of the RNA damage. However,
increasingbodyofevidencesuggestsdetrimentaleﬀectsoftheRNAdamageinproteinsynthesisandtheexistenceofseveralcoping
mechanisms including direct repair and avoiding the incorporation of the damaged ribonucleotides into translational machinery.
Further investigations toward understanding of the consequences and cellular handling mechanisms of the oxidative RNA damage
may provide signiﬁcant insights into the pathogenesis and therapeutic strategies of the neurodegenerative diseases.
Copyright © 2006 Akihiko Nunomura et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Growing body of evidence has indicated that oxidative dam-
age is involved in the pathogenesis of neurodegenerative dis-
eases such as Alzheimer’s disease (AD) and Parkinson’s dis-
ease (PD) [1, 2]. Although RNA in a cell should be sub-
ject to the same oxidative insults as DNA and other cellu-
lar macromolecules, oxidative damage to RNA has not been
the major focus in investigating the magnitude and the bio-
logical consequence. Because RNA is mostly single-stranded
and its bases are not protected by hydrogen bonding and
probably less protected by speciﬁc proteins, RNA may be
more susceptible to oxidative insults than DNA [3]. Indeed,
greater oxidation in cellular RNA than that in DNA was
demonstrated in several experimental studies on nonneu-
ronal cell lines and tissues, where oxidized nucleosides, 8-
hydroxydeoxyguanosine (8OHdG) and 8-hydroxyguanosine
(8OHG), were measured as markers for oxidative damage to
DNA and RNA, respectively [4–6]. It is now becoming evi-
dent that RNA molecules are not only intermediates in the
transfer of genetic information from DNA to proteins but
also key players in many mechanisms controlling expression
of genetic information [7]. Therefore, RNA damage is detri-
mental to cells and may be involved in the pathogenesis of
neurodegenerativediseases[3].Herewereviewrecentstudies
demonstrating RNA oxidation in vulnerable neuronal popu-
lation in several neurological diseases and discuss the biolog-
ical signiﬁcance of the damage to RNA.
RNA OXIDATION IN VARIOUS NEUROLOGICAL
DISEASES AND EXPERIMENTAL CONDITIONS
Among multiple adducts of nucleoside oxidation, 8OHdG
and 8OHG are two of the best characterized and studied
forms of DNA and RNA oxidation, respectively [4, 5]. The
availability of highly speciﬁc antibodies with 8OHdG and
8OHG has enabled us to perform in situ approaches to
nucleoside oxidation in postmortem brain samples taken
from patients with neurological diseases [29, 30]. In 1999,
prominent 8OHdG/8OHG immunoreactions were demon-
strated in the vulnerable neuronal populations in post-
mortem brains of patients with AD and PD [8, 9]. In both
AD and PD, the neuronal 8OHdG/8OHG immunoreac-
tions showed cytoplasmic predominance, which indicated2 Journal of Biomedicine and Biotechnology
Table 1: Summary of studies on RNA oxidation in the central nervous system. (ELISA: enzyme-linked immunosorbent assay; HPLC: high-
performance liquid chromatography; IB: immunoblot; ICC: immunocytochemistry; IEM: immunoelectronmicroscopy; RT-PCR: reverse
transcription and polymerase chain reaction.)
Year Human neurological diseases Materials/Procedures Authors
1999 Alzheimer’s disease Brain (hippocampus/cerebral cortex)/ICC Nunomura et al [8]
Parkinson’s disease Brain (substantia nigra)/ICC Zhang et al [9]
2000 Down syndrome Brain (cerebral cortex)/ICC Nunomura et al [10]
2001 Alzheimer’s disease Brain (hippocampus/cerebral cortex)/IEM Nunomura et al [11]
2002
Dementia with Lewy bodies Brain (hippocampus/cerebral cortex)/ICC Nunomura et al [12, 13]
Familial/sporadic Creutzfeldt-Jakob disease Brain (cerebral cortex)/ICC Guentchev et al [14]
Subacute sclerosing panencephalitis Brain (cerebral cortex)/ICC Hayashi et al [15]
Alzheimer’s disease Cerebrospinal ﬂuid/HPLC Abe et al [16]
Parkinson’s disease/multiple-system atrophy Cerebrospinal ﬂuid/ELISA Kikuchi et al [17]
2003
Alzheimer’s disease Brain (hippocampus/cerebral cortex)/IB and Shan et al [18, 19]
RT-PCR (mRNA)
Parkinson’s disease Cerebrospinal ﬂuid/HPLC Abe et al [20]
2004 Familial Alzheimer’s disease Brain (cerebral cortex)/ICC Nunomura et al [21]
2005
Alzheimer’s disease Brain (hippocampus)/IB and RT-PCR (rRNA) Honda et al [22]
Xeroderma pigmentosum (group A) Brain (globus pallidus)/ICC Hayashi et al [23]
Gerstmann-Straussler-Scheinker disease Brain (hippocampus/cerebral cortex)/ICC Petersen et al [24]
Alzheimer’s disease/mild cognitive impairment Brain (cerebral cortex)/IB (rRNA) Ding et al [25]
Year Experimental conditions Materials/Procedures Authors
2002 Old rat Brain (hippocampus)/ICC Liu et al [26]
2003 Adult rat with intermittent hypoxia Brain (hippocampus)/ICC Row et al [27]
2004 Culture neuron under proteasome inhibition Mixed astrocyte and neuron cultures/ICC and IB Ding et al [28]
that mitochondrial DNA and cytoplasmic RNA in neurons
were major targets of oxidative damage. Because the neu-
ronal 8OHdG/8OHG immunoreactions in AD brain were
diminished greatly by RNase pretreatment but not by DNase
pretreatment,theoxidizednucleosidewaspredominantlyas-
sociated with RNA rather than DNA [8]. This notion was
further supported by the immunoelectron microscopic ob-
servation that most of the oxidized nucleoside was localized
to the ribosomal structures [11].
Similar RNA oxidation in neuronal cytoplasm was ob-
served in brain samples of patients with Down syndrome
[10], dementia with Lewy bodies [12, 13], Creutzfeldt-Jakob
disease [14], and subacute sclerosing panencephalitis [15], as
summarized in Table 1. The oxidative damage to RNA was
demonstrated not only in sporadic form of the diseases but
also in familial form of AD [21] and prion disease, that is,
familial Creutzfeldt-Jakob disease and Gerstmann-Strausler-
Scheinker disease [14, 24]. Furthermore, nuclear DNA ox-
idation and cytoplasmic RNA oxidation were observed in
brains of patients with a genetic defect of nucleotide exci-
sion repair mechanism, xeroderma pigmentosum, showing
cutaneous hypersensitivity to sunlight and progressive neu-
rological disturbances [23].
These immunocytochemical studies demonstrating neu-
ronal RNA oxidation in the neurological diseases were fol-
lowed by biochemical detection of the oxidized nucleoside
in AD brain with immunoblot approaches [18, 19, 22, 25].
Shan et al [18, 19] used Northwestern blotting with a mono-
clonal anti-8OHG antibody, to isolate and identify oxidized
RNA species and showed that signiﬁcant amount of poly
(A)+ mRNA species were oxidized in AD brain. The oxi-
dation to mRNA was further conﬁrmed by cDNA synthe-
sis and Southern blotting of the immunoprecipitated mRNA
species. Densitometric analysis of the Southern blot results
revealed that 30–70% of the mRNAs from AD frontal cor-
tices were oxidized, while only 2% of the mRNAs were ox-
idized in age-matched normal controls [19]. Interestingly,
reverse transcription-PCR and ﬁlter array analyses of the
identiﬁed oxidized mRNAs revealed that some species were
more susceptible to oxidative damage in AD, while no com-
mon motifs or structures were found in the oxidatively sus-
ceptible mRNA species. Some of the identiﬁed known oxi-
dized transcripts were related to AD, which included p21ras,
mitogen-activatedproteinkinase(MAPK)kinase1,carbonyl
reductase, Cu/Zn superoxide dismutase, apolipoprotein D,
calpains,butnotamyloidβ proteinprecursorortau[18].Al-
thoughthesestudiesbyShanetal[18,19]f ocusedo nmRN A
species that account for only a few percent of total cellular
RNA, Honda et al [22] and Ding et al [25] reported that
rRNA, extremely abundant in neurons, contained 8OHG in
AD brain. rRNA showed higher binding capacity to redox-
active iron than tRNA, and consequently oxidation of rRNAAkihiko Nunomura et al 3
by the Fenton reaction formed 13 times more 8OHG than
tRNA [22].
Of note, both immunocytochemical studies [8, 9, 12, 13]
and biochemical studies [18, 25] revealed that the regional
distribution of the RNA oxidation in the brain was consis-
tent with the selective neuronal vulnerability in each neuro-
logical disease. There were increased levels of 8OHG in the
hippocampus and cerebral neocortex in AD as well as in the
substantianigrainPD,whilenoalterationinthe8OHGlevel
was found in the cerebellum in both AD and PD compared
with controls [8, 9, 18, 25].
Signiﬁcantly increased levels of the oxidized RNA nucle-
oside, 8OHG, have been identiﬁed not only in brain tissue
but also in cerebrospinal ﬂuid collected from patients with
AD and PD [16, 17, 20]a sw e l la si ns e r u mo fP Dp a t i e n t s
[17], which indicates that 8OHG is a possible biomarker of
the diseases. As we describe in the next section, 8OHG is a
potent candidate of an early-stage marker of the diseases or a
marker predicting conversion from the prodromal stage into
an early stage of the diseases.
Experimental studies with rodent have shown that neu-
ronalRNAoxidationandspatialmemorydeﬁcitareobserved
in old animals [26] as well as animals with intermittent hy-
poxia [27]. In both aging and hypoxia models, antioxidants
or mitochondrial metabolites can reduce the oxidative dam-
age and the spatial memory deﬁcit. In another experimen-
tal model using mixed astrocyte and neuron cultures [28],
DNA oxidation and RNA oxidation have been observed fol-
lowing proteasome inhibition that is associated with sev-
eral neurodegenerative features such as protein aggregation,
activated apoptotic pathways, and induction of mitochon-
drial disturbances. Interestingly, in this proteasome inhibi-
tion model, neuron underwent larger increases in nucleic
acid oxidation compared to astrocyte cultures, and RNA ap-
peared to undergo a greater degree of oxidation than DNA,
which was exactly identical in AD brain [8].
RNA OXIDATION: AN EARLY-STAGE EVENT IN
THE PROCESS OF NEURODEGENERATION
Because RNA oxidation is involved with a wide variety of
neurologicaldiseases(Table 1),itmaybeconsideredanevent
in common neurodegenerative pathway that occurs in a late
stage of the diseases. However, that is not the case in AD
andPD.Thereisaconsiderableamountofevidencesupport-
ing an early involvement of RNA oxidation in the pathologi-
cal cascade of neurodegeneraton, especially in AD (Table 2).
Namely, RNA oxidation has been observed in postmortem
brains of cases with early-stage AD [11] ,ap r e s y m p t m a t i c
case with familial AD mutation [21], Down syndrome cases
with early-stage AD pathology [10] ,a n ds u b j e c t sw i t hm i l d
cognitive impairment (MCI) who possibly represent podro-
mal stage of AD [25]. Furthermore, the increased level of
RNA oxidation in cerebrospinal ﬂuid is more prominent in
cases with shorter duration of AD and PD [16, 20]. Recent
studies of MCI subjects have demonstrated also increased
oxidation to protein and lipid in postmortem brain [31], in-
creasedlipidperoxidationincerebrospinalﬂuid,plasma,and
urine[32],increasedDNAoxidationinperipheralleukocytes
[33] as well as decreased plasma antioxidant vitamins and
enzymes [34], and decreased plasma total antioxidant capac-
ity [35]. From clinical points of view, the notion of an early
involvementofoxidativedamageinthepathogenesisofthese
degenerative diseases should have a great importance to es-
tablish a diagnostic tool and a therapeutic target, as we have
reviewed recently [36, 37].
Of note, an early-stage involvement of neuronal RNA ox-
idationisidentiﬁednotonlyinage-associatedneurodegener-
ative diseases, but also in cases with subacute sclerosing pa-
nencephalitis that is caused by persistent measles virus in-
fection in the central nervous system and is pathologically
accompanied with brain atrophy and neuroﬁbrillary tangles
[15].
SOURCES OF REACTIVE OXYGEN SPECIES (ROS)
RESPONSIBLE FOR RNA OXIDATION
The brain is especially vulnerable to oxidative damage be-
cause of its high content of easily peroxidizable unsaturated
fatty acids, high oxygen consumption rate (accounting for
20–25% of the total body oxygen consumption, but for less
than 2% of the total body weight), and relative paucity of
antioxidant enzymes compared with other organs (e.g., the
content of catalase in brain is only 10–20% of liver and
heart) [37]. Therefore, neurons are continuously exposed to
ROS such as superoxide, H2O2, and hydroxyl radical that are
produced from the mitochondrial electron transport chain
through normal cellular metabolism. Hydroxyl radical can
diﬀuse through tissue only in the order of several nanome-
ters and superoxide is hardly permeable through cell mem-
brane. In consideration of widespread damage to cytoplas-
mic RNA in the neurodegenerative diseases, RNA species are
likely attacked by hydroxyl radical, which is formed from the
reaction of highly diﬀusible H2O2 with redox-active metals
through Fenton reaction [8, 22]. In AD brain, disrupted mi-
tochondria likely play a central role in producing abundant
ROS as well as supplying redox-active iron into the cytosol
[38, 39]. Indeed, ribosomes puriﬁed from AD hippocam-
pus contain signiﬁcantly higher levels of redox-active iron
compared to controls, and the iron is bound to rRNA [22].
Therefore, mitochondrial abnormality and metal dysregula-
tion are key features closely associated with ROS formation
responsible for the RNA oxidation in AD. Interestingly, both
of the features are found in the substantia nigra of PD also
[36].
RNA OXIDATION AND THE BIOLOGICAL
CONSEQUENCE
Although more than 20 diﬀerent types of oxidatively altered
purine and pyrimidine bases have been detected in nucleic
acids [40], guanine is the most reactive of the nucleic acid
base [41]. Therefore, the oxidized base, 8OHG, is the most
abundant among the oxidized bases [3]. The 8OHG can be
formedinRNAbydirectoxidationofthebaseandalsobythe
incorporation of the oxidized base from the cytosolic pool4 Journal of Biomedicine and Biotechnology
Table 2: Summary of evidence suggesting temporal primacy of RNA oxidation in the process of neurodegeneration.
Materials/subjects Findings
Postmortem brains of patients with
Alzheimer’s disease
RNA oxidation is more prominent in cases with lesser amounts of Aβ plaque
deposition or shorter disease duration [11].
RNA oxidation is more prominent in hippocampal neurons free of neuroﬁbrillary
tangles compared to neurons with neuroﬁbrillary tangles [11].
RNA oxidation is increased in a presymptomatic case with presenilin-1 gene
mutation [21].
Postmortem brains of subjects with mild
cognitive impairment
RNA oxidation is increased in brains of subjects with mild cognitive impairment, who,
at least in part, represent a prodromal stage of dementia [25].
Postmortem brains of patients with
Down syndrome
RNA oxidation precedes Aβ plaque deposition in a series of Down syndrome brains,
a model of Alzheimer’s-type neuropathology [10].
Postmortem brains of patients with
subacute sclerosing panencephalitis
RNA oxidation is observed in cases with shorter disease duration, while lipid
peroxidation is observed in cases with longer disease duration [15].
Cerebrospinal ﬂuid of patients with
Alzheimer’s disease
RNA oxidation is more prominent in cases with shorter disease duration or higher
scores in mini-mental state examination [16].
Cerebrospinal ﬂuid of patients with
Parkinson’s disease
RNA oxidation is more prominent in cases with shorter disease duration [20].
into RNA through the normal action of RNA polymerase
[40, 41]. Not only 8OHG, but also 8-hydroxyadenosine,
5-hydroxycytidine, and 5-hydroxyuridine have been identi-
ﬁed in oxidized RNA [41], which may have altered pairing
capacity and thus may be at the origin of erroneous protein
production. Indeed, the 8OHG can pair with both adenine
and cytosine, and thus the oxidized RNA compromises the
accuracy of translation [40].
The biological consequence of oxidatively damaged
mRNA species has been investigated in vitro by expressing
them in cell lines. Oxidized mRNAs lead to loss of normal
protein level and protein function, and potentially produce
defective proteins leading to protein aggregation, a common
feature of neurodegenerative diseases [18]. Also the biologi-
calconsequenceofribosomaloxidationhasbeeninvestigated
in vitro by translation assay with oxidized ribosomes from
rabbit reticulocyte, which shows a signiﬁcant reduction of
protein synthesis [22]. Recently, a study on brains of subjects
with AD and MCI has demonstrated ribosomal dysfunction
associated with oxidative RNA damage [25]. Isolated polyri-
bosome complexes fromAD and MCIbrains show decreased
rate and capability for protein synthesis without alteration in
the polyribosome content. Decreased rRNA and tRNA levels
and increased 8OHG in total RNA pool, especially in rRNA,
areaccompaniedwiththeribosomaldysfunction,whilethere
is no alteration in the level of initiation factors.
These ﬁndings have indicated that RNA oxidation has
detrimentaleﬀectsoncellularfunctionwhetherthedamaged
RNA species are coding for proteins (mRNA) or performing
translation (rRNA and tRNA). It is noteworthy that studies
onsomeanticanceragentshaveshownthatRNAdamagecan
lead to cell-cycle arrest and cell death, as much as DNA dam-
age does [42] .R N Ad a m a g em a yc a u s ec e lld e a t hvi ap a t h w a y
involving either p53-dependent mechanism associated with
inhibition of protein synthesis or p53-independent mecha-
nism diﬀerent from inhibition of protein synthesis.
COPING WITH RNA DAMAGE
Untilrecently,ithasbeenconsideredthatdamagedRNAmay
be only degraded rather than repaired. However, Aas et al
[43] has suggested that the cells have at least one speciﬁc
mechanism to repair RNA damage, indicating that cells may
have a greater investment in the protection of RNA than pre-
viously suspected [3, 42]. Indeed, alkylation damage in RNA
is repaired by the same mechanism as a DNA-repair, cat-
alyzed in the bacterium Escherichia coli by the enzyme Alk
B, and in humans by the related protein [43]. Alk B and its
homologue hABH3 cause hydroxylation of the methyl group
on damaged DNA and RNA bases, and thus directly reverse
alkylationdamage.AlkBandhABH3,butnothABH2,repair
RNA, since Alk B and hABH3 prefer single-stranded nucleic
acids while hABH2 acts more eﬃciently on double-stranded
DNA.
DNA damage can be repaired not only by the mechanism
of direct reversal of the modiﬁed bases but also by base exci-
sion repair mechanism. Speciﬁc DNA glycosylases excise the
damaged base and DNA polymerases replace the nucleotide
[42, 44]. Furthermore, cells have mechanism of dealing with
nucleotide damage other than direct repair, which seems to
be useful for defense against oxidative damage to both DNA
and RNA. Because oxidation of nucleotides can occur in the
cellular nucleotide pool and the oxidized nucleotide can be
incorporated into DNA and RNA, the mechanism avoiding
such incorporation of the oxidized nucleotide is involved in
coping with nucleic acid damage [40, 42, 44]. MutT proteinAkihiko Nunomura et al 5
inEcolianditsmammalianhomologuesMTH1andNUDT5
participate in this error-avoiding mechanism by hydrolyzing
the oxidized nucleoside diphosphates and/or triphosphates
to the monophosphates [3, 40, 44]. Indeed, the increase in
the production of erroneous proteins by oxidative damage
is 28-fold over the wild-type cells in Ec o l im u t Tdeﬁcient
cells, which is reduced to 1.2- or 1.4-fold by the expression of
MTH1 or NUDT5, respectively [40].
Then, one important question is whether cells have ma-
chineries against oxidatively damaged nucleotides that are
contained in RNA. Recently, proteins that bind speciﬁcally to
8OHG-containing RNA have been reported, namely, Ec o l i
polynucleotide phosphorylase protein (Pnp) and human Y
box-binding protein 1 (YB-1) [45, 46]. The binding of the
speciﬁc protein likely makes the 8OHG-containing RNA re-
sistant to nuclease degradation [45]. However, it has been
proposed that these proteins may recognize and discriminate
the oxidized RNA molecule from normal ones, thus con-
tributingtotheﬁdelityoftranslationincellsbysequestrating
thedamagedRNAfromthetranslationalmachinery[45,46].
It is possible that the RNA quality control mechanisms
are defective or ineﬃcient in cancer cells as well as cells of
neurodegenerativediseases.Furtherelucidationofthemech-
anisms of repair or avoidance of RNA damage and their po-
tential role in preventing human diseases might provide new
a p p r o a c h e st oan u m b e ro fu n r e s o l v e di s s u e so fl i f es c i e n c e ,
while it has not been the major focus in investigation for a
long period [3].
CONCLUSION
An early involvement of RNA oxidation of vulnerable neu-
ronal population in neurodegenerative diseases such as AD
and PD has been demonstrated in immunocytochemical and
biochemical studies. Indeed, oxidized RNA is associated with
a disturbance in protein synthesis in vitro and in vivo. Al-
though there are only a small number of studies suggest-
ing the existence of coping mechanisms for RNA damage at
present, the known mechanisms may be the tip of iceberg of
cellular investment in counteracting the RNA damage. Un-
derstandingoftheconsequencesandcellularhandlingmech-
anisms of the oxidative RNA damage may provide clues to
both basic research and the treatment of the neurodegenera-
tive diseases.
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